EQUITY GI: Improving Care for Black Patients with Gastrointestinal Cancer
This study, called EQUITY GI, aims to improve the quality of care and participation in clinical trials for Black patients with gastrointestinal (GI) cancers, such as colon, rectal, anal, and esophageal cancers. Researchers will work to ensure that participants receive appropriate biomarker testing (looking for specific molecules in tumors or blood that can help guide treatment) and evidence-based care. A group of experts will also periodically review cases to offer treatment recommendations. The study will measure how many Black participants with GI cancer receive biomarker testing over 24 months. You may be able to join if you are an adult (18 years or older) who has been newly diagnosed with a GI cancer and identify as Black.
- Study design
- This is an interventional study planning to enroll 200 participants. It focuses on ensuring appropriate biomarker testing and evidence-based care.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary goal of the study is measured at 24 months, focusing on the biomarker testing rate.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Amit Mahipal, MBBS · PRINCIPAL_INVESTIGATOR · University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Exclusion
What this trial measures
- Biomarker testing rate of Black participants diagnosed with GI cancer24 months
The biomarker testing rate will be estimated based on the number of cases (i.e., participants taking the biomarker testing) using a binomial distribution, and their confidence intervals will be estimated using Wilson's method.23 Potential predictors of the binary outcomes will be identified using multivariable logistic regression.